Canadian Stocks Fall 0.5%
Dow Jones2026/10/23 20:31This article was automatically generated by Dow Jones using technology from Automated Insights.
Stocks in Canada slipped Friday, as the S&P/TSX Composite Index dropped 0.5% to 35788.18.
Among large local companies, Mullen Group was the biggest laggard, plunging 11%, followed by shares of Southern Cross Gold Cons, which plunged 7.9%. Shares of Perpetua Resources fell 4.7%.
Surge Energy was the biggest leader during the session, rising 4.5%, and Tenaz Energy gained 4.5%. Saturn Oil & Gas rounded out the top three movers, as shares increased 4.3%.
Stock indexes in the U.S. fell with the Dow Jones Industrial Average falling 1.2%. Meanwhile, the S&P 500 Index fell 0.5%, and the Nasdaq Composite Index dropped 0.2%.
On the currency front, the WSJ Dollar Index rose 0.1% to 96.87. The Canadian dollar held steady against the U.S. dollar at US$0.71.
In the bond markets, the 10-year Canadian government bond yield rose 5.94 basis points to 3.843%.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 23, 2026 16:31 ET (20:31 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trump Media & Technology Group plunges over 24%, hitting a new low since listing.
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver
Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.